Stock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint

Stock Track

Apr 01

Shares of Alphamab Oncology (ALPHAMAB-B, 09966.HK) surged 5.13% during intraday trading on Wednesday, following the announcement of positive clinical trial results.

The company reported that its Phase III Neo-Healer study evaluating KN026 in combination with HB1801 for the neoadjuvant treatment of HER2-positive breast cancer successfully met its primary endpoint. The trial showed improved complete response outcomes compared to the current standard treatment regimen. This success supports the broader late-stage development strategy for KN026 across HER2-positive breast cancer and gastric cancer indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1139460182"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139460182\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139460182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139460182","market":"hk","top_or_hot":-1,"title":"Stock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint","media":"Stock Track","content":"<p>Shares of Alphamab Oncology (ALPHAMAB-B, 09966.HK) surged 5.13% during intraday trading on Wednesday, following the announcement of positive clinical trial results.</p><p>The company reported that its Phase III Neo-Healer study evaluating KN026 in combination with HB1801 for the neoadjuvant treatment of HER2-positive breast cancer successfully met its primary endpoint. The trial showed improved complete response outcomes compared to the current standard treatment regimen. This success supports the broader late-stage development strategy for KN026 across HER2-positive breast cancer and gastric cancer indications.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Alphamab Oncology (ALPHAMAB-B, 09966.HK) surged 5.13% during intraday trading on Wednesday, following the announcement of positive clinical trial results.</p><p>The company reported that its Phase III Neo-Healer study evaluating KN026 in combination with HB1801 for the neoadjuvant treatment of HER2-positive breast cancer successfully met its primary endpoint. The trial showed improved complete response outcomes compared to the current standard treatment regimen. This success supports the broader late-stage development strategy for KN026 across HER2-positive breast cancer and gastric cancer indications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1139460182","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139460182","pubTimestamp":1775007678,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Alphamab Oncology (ALPHAMAB-B, 09966.HK) surged 5.13% during intraday trading on Wednesday, following the announcement of positive clinical trial results.The company reported that its Phase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B"},"translate_title":"股票追踪|康宁杰瑞-B乳腺癌III期试验达到主要终点后盘中暴涨5.13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"Shares of Alphamab Oncology (ALPHAMAB-B, 09966.HK) surged 5.13% during intraday trading on Wednesday, following the announcement of positive clinical trial results.The company reported that its Phase III Neo-Healer study evaluating KN026 in combination with HB1801 for the neoadjuvant treatment of HER2-positive breast cancer successfully met its primary endpoint. The trial showed improved complete response outcomes compared to the current standard treatment regimen. This success supports the broader late-stage development strategy for KN026 across HER2-positive breast cancer and gastric cancer indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}